Evidence map›Paper›PMID 40817159›Full record

ArticleBritish journal of cancer2025

The lung immune prognostic index stratifies the occurrence of checkpoint inhibitor pneumonitis in advanced non-small cell lung cancer patients: a multi-institutional cohort study.

Bingxin Gong, Yusheng Guo, Qi Wan, Jie Lou, Guisheng Zhang, Yi Li, Feng Pan, Lian Yang

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Bingxin Gong *Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Yusheng Guo *Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Qi Wan *Department of Radiology, the Key Laboratory of Advanced Interdisciplinary Studies Center, National Center for Respiratory Medicine, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Jie LouDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Guisheng ZhangCollege of Medical Technology and Engineering, Henan University of Science and Technology, Luoyang, China.
Yi LiDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Feng PanDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. uh_fengpan@hust.edu.cn.
Lian YangDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. yanglian@hust.edu.cn.ORCID http://orcid.org/0000-0003-4664-2474

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLung immune prognostic index (LIPI) is associated with survival outcomes in patients with non-small cell lung cancer (NSCLC) receiving immunotherapy, but the association with the occurrence of checkpoint inhibitor pneumonitis (CIP) is unclear.

methodsWe retrospectively included 1824 patients with advanced NSCLC who received immune checkpoint inhibitors (ICIs) at two institutions. Cox regression analysis and cumulative incidence curve were used to evaluate the predictive value of LIPI. Additionally, we performed competing risk analysis using Fine-Gray regression and cumulative incidence curves.

resultsDuring a median follow-up of 15 months, 99 patients developed CIP. Compared with the good LIPI group, the intermediate LIPI group (HR 1.87, P = 0.007) and poor LIPI group (HR 4.39, P < 0.001) had a higher risk of CIP. Furthermore, we found LIPI was an independent predictor for intermediate-grade CIP (intermediate LIPI: HR 2.11, P = 0.056; poor LIPI: HR 4.51, P = 0.002) and high-grade CIP (intermediate LIPI: HR 6.94, P = 0.014; poor LIPI: HR 44.01, P < 0.001), but not for low-grade CIP (intermediate LIPI: HR 1.31, P = 0.392; poor LIPI: HR 0.72, P = 0.656). Similar results were obtained after competing risk analysis.

conclusionsLIPI grade shows potential in predicting the risk of CIP during immunotherapy and could be valuable in clinical management.

Indexed as

Carcinoma, Non-Small-Cell LungImmune Checkpoint InhibitorsLung NeoplasmsPneumoniaAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesImmune Checkpoint Inhibitors

Identifiers

PMID40817159
PMCPMC12533072

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.